On Friday 1st October, 1-2pm, Helen Williams, National Specialty Adviser for Cardiovascular Disease and Consultant Pharmacist extraordinaire, discussed the latest addition to the cholesterol management portfolio, Inclisiran, and its place in therapy.
The presentation was followed by a Q & A session.
Inclisiran webinar - Correction
During the PrescQIPP Inclisiran webinar on 1st October, a question was asked regarding the price differential between primary and secondary care, as described in the inclisiran Medicines Optimisation Pack.
In response to the question, the Accelerated Access Collaborative (AAC) advised that there was central funding for a discounted price for secondary care, and that therefore inclisiran would be the same price in primary and secondary care.
However, following the webinar, the AAC clarified this response and confirmed that the cost of inclisiran when dispensed in hospital would be at the contract price paid by NHS England, and that central funding was only available for inclisiran when supplied in primary care either via the FP10 or FP34D route, at that time.
From January 2022, central NHS England funding arrangements were also made available for inclisiran when prescribed and supplied by secondary care.
A summary of the current funding arrangements for inclisiran in primary and secondary care, issued by NHS England in February 2022, is available on the Wessex Academic Health Sciences Network website at https://www.weahsn.net/wp-content/uploads/2022/02/B1361_Summary-info-on-funding-and-supply-of-inclisiran.pdf. This includes the updated advice regarding central funding provision for inclisiran in secondary care from 1st January 2022.
More information regarding the Accelerated Access Collaborative and its work can be found at https://www.england.nhs.uk/aac/ and the Academic Health Sciences Network at https://www.england.nhs.uk/ourwork/part-rel/ahsn/
